share_log

Eli Lilly and Co | SC TO-T/A: Third party tender offer statement (Amendment)

Eli Lilly and Co | SC TO-T/A: Third party tender offer statement (Amendment)

礼来 | SC TO-T/A：发行招标公告
美股sec公告 ·  08/05 17:07
Moomoo AI 已提取核心信息
Eli Lilly and Company, through its subsidiary Rainier Acquisition Corporation, has made a tender offer to acquire all outstanding shares of Morphic Holding, Inc. at $57.00 per share in cash. The offer, initially filed on July 19, 2024, is set to expire on August 15, 2024, unless extended or terminated earlier. Amidst this acquisition process, several lawsuits have been filed against Morphic and its board members, alleging failure to disclose material information in connection with the tender offer and seeking injunctions, revisions to disclosures, rescission of the transactions, or damages. The complaints were filed by purported Morphic stockholders in both federal and state courts. Eli Lilly has indicated that additional lawsuits may arise but will not necessarily announce such complaints unless they contain materially new or different allegations.
Eli Lilly and Company, through its subsidiary Rainier Acquisition Corporation, has made a tender offer to acquire all outstanding shares of Morphic Holding, Inc. at $57.00 per share in cash. The offer, initially filed on July 19, 2024, is set to expire on August 15, 2024, unless extended or terminated earlier. Amidst this acquisition process, several lawsuits have been filed against Morphic and its board members, alleging failure to disclose material information in connection with the tender offer and seeking injunctions, revisions to disclosures, rescission of the transactions, or damages. The complaints were filed by purported Morphic stockholders in both federal and state courts. Eli Lilly has indicated that additional lawsuits may arise but will not necessarily announce such complaints unless they contain materially new or different allegations.
伊莱利莱药公司通过其子公司Rainier Acquisition Corporation，已经发起了对Morphic Holding，Inc.所有未结购股票的收购要约，每股57.00美元现金。该要约最初于2024年7月19日提交，将于2024年8月15日到期，除非提前或终止。在此收购过程中，已有几起诉讼针对Morphic及其董事会成员提起，指控其未披露与收购要约有关的重要信息，并寻求禁令、披露的修订、交易的撤销或赔偿。这些投诉是由名为Morphic股东在联邦和州法院提起的。伊莱利莱已经表明，可能会出现其他诉讼，但除非这些投诉包含新的或不同的指控，否则不会一定公布。
伊莱利莱药公司通过其子公司Rainier Acquisition Corporation，已经发起了对Morphic Holding，Inc.所有未结购股票的收购要约，每股57.00美元现金。该要约最初于2024年7月19日提交，将于2024年8月15日到期，除非提前或终止。在此收购过程中，已有几起诉讼针对Morphic及其董事会成员提起，指控其未披露与收购要约有关的重要信息，并寻求禁令、披露的修订、交易的撤销或赔偿。这些投诉是由名为Morphic股东在联邦和州法院提起的。伊莱利莱已经表明，可能会出现其他诉讼，但除非这些投诉包含新的或不同的指控，否则不会一定公布。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息